Appendicitis, 2002: relationship between payors and outcome.

Am Surg

Department of Surgical Education, Santa Barbara Cottage Hospital, Santa Barbara, California 93102, USA.

Published: October 2003

As the status of health-care insurance changes in the United States, studies have indicated that uninsured patients are less likely to receive timely and quality health care. Previous studies of appendicitis have shown that insurance status may effect the stage of presentation and outcome. However, these studies were based on databases lacking information regarding stage of presentation, timeliness of diagnosis and treatment, and character of hospitalization (length of stay, duration of antibiotic therapy, hospital costs). We accomplished a case control study, retrospective analysis of 975 patients treated for acute appendicitis between January 1996 and December 1999. Times to operation, number of preoperative outpatient visits, number of studies, severity of presentation, length of antibiotics and hospital stay, and hospital costs were analyzed [analysis of variance (ANOVA) techniques, P < 0.05 significant]. We sought answers to the following: (1) Did insurance status affect the timeliness of diagnosis and treatment? (2) Did insurance status affect the stage of presentation? (3) Did insurance status affect hospitalization, as measured by length of stay, duration of antibiotic therapy, and hospital costs? (4) Did age affect outcome independent of insurance status? There were no correlations between insurance status and timeliness of diagnosis or severity of presentation. Length of stay and hospital costs were also not different between insurance categories. Pediatric patients (< 12 years old) and the elderly (> 65 years old) presented with more advanced appendicitis, independent of insurance category. In contrast to previously published data, the treatment of acute appendicitis is not affected by insurance coverage in the sample community. Age and timeliness of presentation were the only factors correlating to outcomes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

insurance status
20
timeliness diagnosis
12
length stay
12
hospital costs
12
status affect
12
insurance
10
appendicitis insurance
8
stage presentation
8
stay duration
8
duration antibiotic
8

Similar Publications

Importance: Immunocompromised status is a risk factor for severe SARS-CoV-2 infection. Little is known about how systemic corticosteroid dose and concurrent use of immunosuppressants are associated with COVID-19 outcomes.

Objective: To assess the association between corticosteroid dose/duration and concurrent immunosuppressant use on COVID-19 hospitalisation and death in the era of COVID-19 vaccinations.

View Article and Find Full Text PDF

Background: Surgical resection is the gold standard treatment for early-stage non-small cell lung cancer (NSCLC). Prior studies have found that delayed treatment carries risk of disease progression. However, factors that predict delay to surgery are relatively understudied.

View Article and Find Full Text PDF

Cryopreserved sperm among patients with Oligoasthenoteratozoospermia.

Eur J Obstet Gynecol Reprod Biol

December 2024

Sperm Bank & Andrology Unit, Shamir Medical Center, Zerifin, Israel; IVF Department, Shamir Medical Center, Zerifin, Israel; Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.

Objectives: This study investigates sperm utilization and disposal patterns in Oligoasthenoteratozoospermia (OAT) patients undergoing long-term sperm storage. OAT is a major contributor to male infertility. Cryopreservation is a common practice as a "fertility insurance" in case of further deterioration until azoospermia.

View Article and Find Full Text PDF

Posttransplant diabetes mellitus (PTDM) is associated with significant morbidity and mortality in liver transplant recipients (LTRs). We used the Organ Procurement and Transplantation Network (OPTN) database to compare the incidence of developing PTDM across the United States and develop a risk prediction model for new-onset PTDM using OPTN region as well as donor-related, recipient-related, and transplant-related factors. All US adult, primary, deceased donor, LTRs between January 1, 2007, and December 31, 2016, with no prior history of diabetes noted, were identified.

View Article and Find Full Text PDF

Five-Year Fracture Rate for Transgender and Gender Diverse Patients on Gender-Affirming Hormone Therapy.

J Am Acad Orthop Surg

December 2024

From the University of Michigan Medical School, Ann Arbor, MI (Jacobson), the Department of Physical Medicine and Rehabilitation (Whitney), Department of Orthopedic Surgery (Mamdouhi and Ahn), Consulting for Statistics, Computing and Analytics Research (Janney), and Department of Family Medicine (Blaszczak), University of Michigan, Ann Arbor, MI, and the Department of Orthopaedics, Emory University and Grady Health, Atlanta, GA (Ahn).

Introduction: Gender-affirming hormone therapy (GAHT) is a cornerstone of gender-affirming care for transgender and gender diverse (TGD) patients, with a direct biological role on bone metabolism. However, a paucity of data describes how GAHT influences fracture rate over time. The study's primary objective was to describe the 5-year all-cause fracture incidence rate (IR) among TGD patients initiating estrogen-based GAHT (E-GAHT) or testosterone-based GAHT (T-GAHT), compared with TGD patients not using GAHT (non-GAHT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!